Advances in clinical and experimental medicine : official organ Wroclaw Medical University · 2026
Nonalcoholic fatty liver disease and cardiovascular risk in patients with unstable angina: A 3-year prospective follow-up study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shi Pei, Meng Xiaojuan
Аннотация
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a multisystem disorder with potential cardiovascular consequences. Its role in patients with unstable angina (UA), a high-risk manifestation of coronary artery disease (CAD), remains underexplored.
OBJECTIVES: To evaluate the impact of NAFLD on long-term cardiovascular outcomes in patients with UA.
MATERIAL AND METHODS: This prospective cohort study enrolled 150 patients diagnosed with UA, who were categorized into NAFLD and non-NAFLD groups based on imaging and clinical criteria. Baseline metabolic and liver function parameters were recorded. Patients were followed for 3 years to document major adverse cardiovascular events (MACE). Kaplan-Meier analysis was used to assess event-free survival, and multivariate logistic regression was performed to identify independent predictors of MACE.
RESULTS: Patients with NAFLD exhibited worse metabolic and liver function profiles than those without NAFLD. During the 3-year follow-up period, the incidence of MACE was significantly higher in the NAFLD group. Kaplan-Meier analysis revealed shorter MACE-free survival time among patients with NAFLD (p < 0.05). However, in multivariate logistic regression analysis, diabetes mellitus, but not NAFLD, remained an independent predictor of MACE after adjustment for potential confounding factors.
CONCLUSIONS: Nonalcoholic fatty liver disease is associated with metabolic dysfunction and an increased risk of cardiovascular events in patients with UA. Although it is not an independent predictor of MACE, its presence may indicate a higher long-term cardiovascular risk and should be considered in clinical risk stratification.
OBJECTIVES: To evaluate the impact of NAFLD on long-term cardiovascular outcomes in patients with UA.
MATERIAL AND METHODS: This prospective cohort study enrolled 150 patients diagnosed with UA, who were categorized into NAFLD and non-NAFLD groups based on imaging and clinical criteria. Baseline metabolic and liver function parameters were recorded. Patients were followed for 3 years to document major adverse cardiovascular events (MACE). Kaplan-Meier analysis was used to assess event-free survival, and multivariate logistic regression was performed to identify independent predictors of MACE.
RESULTS: Patients with NAFLD exhibited worse metabolic and liver function profiles than those without NAFLD. During the 3-year follow-up period, the incidence of MACE was significantly higher in the NAFLD group. Kaplan-Meier analysis revealed shorter MACE-free survival time among patients with NAFLD (p < 0.05). However, in multivariate logistic regression analysis, diabetes mellitus, but not NAFLD, remained an independent predictor of MACE after adjustment for potential confounding factors.
CONCLUSIONS: Nonalcoholic fatty liver disease is associated with metabolic dysfunction and an increased risk of cardiovascular events in patients with UA. Although it is not an independent predictor of MACE, its presence may indicate a higher long-term cardiovascular risk and should be considered in clinical risk stratification.